Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK

Why It Matters

By creating African‑specific safety and immunogenicity data and a local production pathway, ACT‑CHIK could dramatically improve access to chikungunya vaccination where the disease burden is rising, supporting regional health security and the continent’s vaccine‑self‑sufficiency goals.

Key Takeaways

• ACT-CHIK receives €15.3M (~$16.7M) EU funding.
• Phase Ib/III trial will enroll 940 participants in four African countries.
• MV-CHIK uses measles virus vector; safety shown in 600 adults.
• Technology transfer targets Institut Pasteur de Dakar, WHO‑prequalified manufacturer.
• Supports African Union aim for 60% local vaccine production by 2040.

Pulse Analysis

Chikungunya, transmitted by Aedes mosquitoes, has surged across Africa over the past two decades, yet it remains under‑diagnosed and under‑treated. Existing vaccines are largely limited to travelers because of high costs and supply constraints. The MV‑CHIK candidate, a live‑attenuated recombinant vaccine built on the proven measles Schwarz strain, has already cleared Phase I/II trials in Europe, the United States and Puerto Rico, demonstrating a solid safety and immunogenicity profile in roughly 600 adults. This scientific foundation sets the stage for a broader rollout in regions where the disease is endemic.

ACT‑CHIK, funded with €15.3 million from the EU’s Horizon Europe EDCTP3 programme, will conduct a multicentre Phase Ib/III study across Rwanda, Kenya, Nigeria and Senegal. By enrolling 940 participants—including adults, adolescents and children—in both endemic and non‑endemic settings, the trial will generate the critical data needed for regulatory approval and for tailoring dosing strategies to African populations. The project also leverages the Pasteur Network, with Fiocruz in Brazil preparing clinical‑trial material and the Institut Pasteur de Dakar slated to receive the full manufacturing technology, positioning the continent to produce the vaccine locally.

Beyond the immediate health benefits, ACT‑CHIK aligns with the African Union’s target of meeting 60 % of the continent’s vaccine demand by 2040 and the EU’s Team Europe initiative on manufacturing and access. By establishing a regulatory pathway that engages national authorities and WHO pre‑qualification teams, the programme could set a precedent for future African‑led vaccine development pipelines. Successful technology transfer would not only lower costs and improve supply resilience for chikungunya but also strengthen Africa’s broader biotech infrastructure, fostering a more self‑sufficient response to emerging infectious threats.